Tolerance, variability, and pharmacokinetics of bevacizumab biosimilars in Chinese healthy male subjects

被引：0
|
作者：
Hong Zhang
Qingmei Li
Xiaoxue Zhu
Cuiyun Li
Xiaojiao Li
Chengjiao Liu
Yue Hu
Guiling Chen
Haijing Wei
Jing Wang
Zhenwei Shen
Yanhua Ding
机构：
[1] The First Hospital of Jilin University,Phase I Clinical Research Center
[2] The First Hospital of Jilin University,undefined
来源：
Cancer Chemotherapy and Pharmacology | 2018年 / 82卷
关键词：
Bevacizumab; Biosimilar; Immunogenicity; Pharmacokinetics; Inter-subject variability;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：615 / 623
页数：8
相关论文
共 50 条
  • [1] Tolerance, variability, and pharmacokinetics of bevacizumab biosimilars in Chinese healthy male subjects
    Zhang, Hong
    Li, Qingmei
    Zhu, Xiaoxue
    Li, Cuiyun
    Li, Xiaojiao
    Liu, Chengjiao
    Hu, Yue
    Chen, Guiling
    Wei, Haijing
    Wang, Jing
    Shen, Zhenwei
    Ding, Yanhua
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2018, 82 (04) : 615 - 623
  • [2] Pharmacokinetics of Terazosin Enantiomers in Healthy Chinese Male Subjects
    Liu, Man
    Zhang, Dan
    Yang, Man
    Zhao, Ting
    Wang, Xiaolin
    Zhang, Yanan
    Han, Jing
    Liu, Huichen
    CHIRALITY, 2012, 24 (12) : 1047 - 1050
  • [3] Inter- and Intra-individual Variability in the Pharmacokinetics of Agomelatine Tablets in Chinese Healthy Male Subjects
    Wang, X. -l.
    Du, A. -h.
    Zhang, D.
    Meng, L. -j.
    Liu, M.
    Zhang, L. -n.
    Zhao, H. -n.
    Liu, H. -c.
    DRUG RESEARCH, 2015, 65 (10) : 552 - 554
  • [4] Single-dose pharmacokinetics of levetiracetam in healthy Chinese male subjects
    Zhao, Qian
    Jiang, Ji
    Li, XiaoMing
    Lu, Zhihong
    Hu, Pei
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2007, 63 (05) : 614 - 617
  • [5] Evaluation of Olaparib Tablet Safety and Pharmacokinetics in Healthy Chinese Male Subjects
    Dong, Ruihua
    Chen, Jingcheng
    Guo, Nini
    Yang, Yingying
    Wu, Jingxuan
    Wang, Xiaoru
    Song, Yuqin
    Zhang, Xueyuan
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2024, 18 : 5529 - 5539
  • [6] A phase I pharmacokinetics study comparing PF-06439535 (a potential biosimilar) with bevacizumab in healthy male volunteers
    Knight, Beverly
    Rassam, Danielle
    Liao, Shanmei
    Ewesuedo, Reginald
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2016, 77 (04) : 839 - 846
  • [7] The pharmacokinetics of lamivudine in healthy Chinese subjects
    Jiang, J
    Hu, P
    Xie, H
    Chen, H
    Fan, F
    Harker, A
    Johnson, MA
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1999, 48 (02) : 250 - 253
  • [8] A phase I pharmacokinetics study comparing PF-06439535 (a potential biosimilar) with bevacizumab in healthy male volunteers
    Beverly Knight
    Danielle Rassam
    Shanmei Liao
    Reginald Ewesuedo
    Cancer Chemotherapy and Pharmacology, 2016, 77 : 839 - 846
  • [9] Exenatide pharmacokinetics in healthy Chinese subjects
    Zhao, X.
    Cui, Y. M.
    Zhou, Y.
    Zhang, H. L.
    Yeo, K. P.
    Linnebjerg, H.
    Tham, L. S.
    Kothare, P.
    Teng, L. L.
    Mace, K.
    Soon, D.
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2008, 46 (09) : 459 - 465
  • [10] A randomized, double-blind, parallel-group phase I study comparing the pharmacokinetics, safety, and immunogenicity of LY01008, a candidate bevacizumab biosimilar, with its reference product Avastin® in healthy Chinese male subjects
    Zhou, Renpeng
    Yang, Jingjing
    Liu, Yueyue
    Zhang, Qian
    Lu, Chao
    Tang, Ke
    Li, Xiao
    Tang, Wei
    Gao, Emei
    Wu, Can
    Dou, Changlin
    Hu, Wei
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2022, 22 (02) : 263 - 269
12345